Logo image of PRTG

PORTAGE BIOTECH INC (PRTG) Stock Fundamental Analysis

NASDAQ:PRTG - Nasdaq - VGG7185A1369 - Common Stock - Currency: USD

4.41  -0.15 (-3.29%)

After market: 5.39 +0.98 (+22.22%)

Fundamental Rating

2

PRTG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While PRTG seems to be doing ok healthwise, there are quite some concerns on its profitability. PRTG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRTG had negative earnings in the past year.
In the past year PRTG has reported a negative cash flow from operations.
PRTG had negative earnings in each of the past 5 years.
PRTG had a negative operating cash flow in each of the past 5 years.
PRTG Yearly Net Income VS EBIT VS OCF VS FCFPRTG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

PRTG has a worse Return On Assets (-1357.19%) than 99.47% of its industry peers.
The Return On Equity of PRTG (-2830.59%) is worse than 84.96% of its industry peers.
Industry RankSector Rank
ROA -1357.19%
ROE -2830.59%
ROIC N/A
ROA(3y)-360.91%
ROA(5y)-218.97%
ROE(3y)-674.91%
ROE(5y)-409.17%
ROIC(3y)N/A
ROIC(5y)N/A
PRTG Yearly ROA, ROE, ROICPRTG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRTG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRTG Yearly Profit, Operating, Gross MarginsPRTG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, PRTG has less shares outstanding
The number of shares outstanding for PRTG has been reduced compared to 5 years ago.
The debt/assets ratio for PRTG is higher compared to a year ago.
PRTG Yearly Shares OutstandingPRTG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
PRTG Yearly Total Debt VS Total AssetsPRTG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -66.59, we must say that PRTG is in the distress zone and has some risk of bankruptcy.
PRTG has a Altman-Z score of -66.59. This is amonst the worse of the industry: PRTG underperforms 95.58% of its industry peers.
There is no outstanding debt for PRTG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -66.59
ROIC/WACCN/A
WACCN/A
PRTG Yearly LT Debt VS Equity VS FCFPRTG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

PRTG has a Current Ratio of 1.73. This is a normal value and indicates that PRTG is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.73, PRTG is doing worse than 80.18% of the companies in the same industry.
PRTG has a Quick Ratio of 1.73. This is a normal value and indicates that PRTG is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of PRTG (1.73) is worse than 78.94% of its industry peers.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
PRTG Yearly Current Assets VS Current LiabilitesPRTG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for PRTG have decreased strongly by -403.10% in the last year.
EPS 1Y (TTM)-403.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PRTG will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.77% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.49%
EPS Next 2Y41.28%
EPS Next 3Y25.91%
EPS Next 5Y14.77%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRTG Yearly Revenue VS EstimatesPRTG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
PRTG Yearly EPS VS EstimatesPRTG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PRTG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRTG Price Earnings VS Forward Price EarningsPRTG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTG Per share dataPRTG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

PRTG's earnings are expected to grow with 25.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.28%
EPS Next 3Y25.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRTG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PORTAGE BIOTECH INC

NASDAQ:PRTG (1/31/2025, 8:00:00 PM)

After market: 5.39 +0.98 (+22.22%)

4.41

-0.15 (-3.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-26 2024-11-26/amc
Earnings (Next)02-26 2025-02-26
Inst Owners10.77%
Inst Owner Change0%
Ins Owners33%
Ins Owner ChangeN/A
Market Cap4.63M
Analysts43.33
Price TargetN/A
Short Float %3.62%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.84
P/tB 1.84
EV/EBITDA N/A
EPS(TTM)-129.8
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-11.94
FCFYN/A
OCF(TTM)-11.94
OCFYN/A
SpS0
BVpS2.39
TBVpS2.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1357.19%
ROE -2830.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-360.91%
ROA(5y)-218.97%
ROE(3y)-674.91%
ROE(5y)-409.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z -66.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-403.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y99.49%
EPS Next 2Y41.28%
EPS Next 3Y25.91%
EPS Next 5Y14.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.29%
OCF growth 3YN/A
OCF growth 5YN/A